CDKN2A and type 2 diabetes mellitus: Thus, targeting alternative CDKN2A signaling pathways that may not be involved in tumor suppressive and anti-proliferative effects, but which are driving the browning process in APs, may represent a new strategy to reprogram the cellular response and develop therapeutic approaches against obesity and T2D.